Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you move back a day, you’ll hit SEC filing requirements. Fins are due by 6/30 at latest.
You mean realism? Take a look at where Adderall ER has done over several years?5%? Not even close. Why assume penetration will be closer to IR or even half of it when we can’t get there with ER?
Prasco will help move things along with ER, but this board has no sense of realism. Let’s ignore facts and simply opt for pie in the sky.
Where are we from global ambitions? Dexcel hasn’t moved going on 3 years now.
I couldn’t care less if you call me the animal of your choosing. Just so you know GOAT has a much different meaning today.
My job is to provide a balance to this board. Choose the animal of your choice.
It’s as annoying as sleuth’s running commentary of “you don’t know why you are on this board, do you?”
Be objective, be realistic. Nasrat can’t hit near term goals working with smaller drugs and the FDA and yet we believe his billion dollar market ambitions. That’s an issue. It sucks, but it’s what has actually happened. Don’t ignore what’s right under your nose.
Math is wrong from beginning. That $10 market with known drugs will shrink. Vyvanse is half of it and market will greatly shrink when generics can get API and actually start penetrating the market. The question is by how much with 10+ competitors aching to get piece of pie, 50%, 60%?
Will there be future products to grow total penetrate market beyond what we already know? Highly likely if pipeline can keep moving forward and submissions approved.
Management is protected by forward looking language. Doing what you say you intend to do, hope to do and actually doing it builds credibility. No one has a crystal ball and even regarding near term sales expectations midway through quarter have been drastically missed. I can’t tell if Nasrat is shooting from the hip in some commentary or just unrealistically optimistic, trying to prop up share price on hope, not close enough to the business or a clueless nincompoop? One thing that has been consistent is the abysmal external communication.
He also said NASDAQ many years ago. He misses self imposed timeframes and continually deflects. It’s always someone else’s fault.
They haven’t been filing them separately since SequestOx. They have been putting them in the Q’s and K’s. We may not see the CRL wording until 10K in June.
Some companies are better than others others, but it’s all Elite really has at this point, insider ownership + retail.
Retail shareholders are ignored 99% of the time.
You can find anything you want online. The sales growth will speak for itself.
It sure we’ll have any revenue from Vigabatrin. We no longer own it and are only a contract manufacturer. Time is eating away at that contract…
We did trade over 5M on 2/23/24,
8/23/23 & 8/28/23. We even hit 10M on 8/22/23. Looking forward to the daily average hitting 5M.
I don’t think original poster was saying billion shares were traded daily, but rather outstanding.
AI generated article. Dollar difference of “significant growth” in short positions is about $12K, or about 0.15% of O/S count.
You are correct. As of last 10K he listed 295M at 29.1%, which differs from recent Form 4.
Form 4’s filed today. One is amendment. Total ownership ~220M shares owned by Nasrat that have been disclosed.
Agreed we knew it was coming. I misinterpreted your comment thinking it wasn’t dilution.
Haven’t sold a single share. I haven’t day traded for while. Never did with Elite.
You do realize it was dilutive, right?
It’s payment delay, but 80M in dilutive shares to the O/S count nonetheless.
Well the 2 SEC dilutive filings from Friday might be the factor. It’s on little volume. Daily volume has been low the past few weeks now.
I didn’t say that I was, but you should have the mindset of one.
Hey noob - Because that’s the whole premise of an investor, especially activist investors that care about their investment. When something isn’t right, they aren’t lemmings, they let their voice be heard.
I don’t think either will happen. Significant amount of work to be done towards either. Perhaps later this year or early next.
Who did with fumbles and hose ups along the way? Hail to Nasrat is all you do and ignore the ridiculous mistakes. I’m sorry you are blind to reality.
Why do you think Nasrat is the only person on creation that could have helped Elite? Therein lies a sad assumption.
I think it was PharmaSleuth that initially posted that. I think it was only value added comment other than “do you know why you are here?” every single post.
But primarily the mfg revenue
From the 50% Elite owns.
If it’s at the same or similar multiple of crappy drugs Mikah sold Elite in past, he can keep it.
The result of another company owning 50% Adderalls still has no different impact than Mikah owning it. I’m not seeing the benefit to shareholders other than CEO being able to package a side deal to future acquirers to include Mikah. Would love to hear why you or others believe otherwise. I love a good debate and would be more than happy to be swayed otherwise. I’ve worked closely to too many CEOs that put on a public appearance that greatly differs to strings pulled behind scenes. Take a look at BODs today. Public companies have become a I’ll scratch your back if you scratch mine culture. It’s really sad, but real.
How does Mikah’s 50% purchase have any impact on Elite?
I see a CEO that has chips on one side of the table, but can see everyone’s cards in any potential transaction.
CEO claimed that Mikah’s ownership prevents a company from owning 50% Adderall rights can potentially be harmful to Elite. I think that is a very biased view from someone that was drooling at the opportunity. Not sure I agree with CEO’s view, but c’est la vie. To each their own.
Désolé mais je ne peux pas répondre en privé. :)
Je ne suis pas français mais j’ai vécu dans le sudouest de la France pendant 2 ans. Je me suis spécialisé en français à l’université ainsi qu’en finance et commerce international. C’est rare que j’ai l’occasion de parler en français sauf avec les ouest-Africains de temps en temps.
There is much to be excited about, but you can’t handle reality? Ignoring history doesn’t bode well.
Ridiculous post. The question pertained to business relationships.
This is a new relationship. Burel hasn’t really done much. We have high hopes and expectations for Prasco, but I think it’s safe to say last Q did not meet those expectations, which is why SP dropped. With a full quarter now under our belt, let’s see what the potential is.
Good call on TAGI, this is a long-term one they have relied on.
Mikah was mentioned in my post.
Do you count CEO offloading overpriced drugs that never could make it to market as a win for Elite? Once again, see it as you will, but this is non-arms length. Never kosher from investor standpoint, unless you’re the CEO here, then there is extreme bias.
Absolutely. Elite doesn’t have the greatest history of relationships. In fact the only two long-term relationships they have relied on are Lincoln for the dilutive financing and Mikah, owned by the CEO.
Sungen was a decent relationship win as we have we have Adderalls, but how is approved antibacterial ANDA from couple years ago faring as status of the relationship?
For one reason or another, Elite has historically primarily treated relationships as individual transactions other than 2 mentioned above.
What makes you say that? They simply helped facilitate the recent transaction. Let’s not perform math that doesn’t exist.
One too many drinks at the pub today to be coherent?
I’ve worked for fortune 500’s that made greater investment in leadership team through grants and options than actual investments in the company. Simply a way to neutralize dilution. The benefit of buybacks are questionable, however, we have such a bloated float that a R/S is more likely the realistic option to normalize share structure and get off OTC.
There are pros and cons to this filing. Nice to see the liabilities finally get cleaned up. Sad to see the amount of incremental dilution going to Nasrat after he’s already diluted this company by almost 3x prior to his start, much of which was driven by SequestOx and some tiny drugs that Elite bought from Mikah that will never go to market and provide an ROI to shareholders.